<DOC>
	<DOCNO>NCT00112892</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop growth tumor cell , either kill cell stop dividing . Selenium may allow high dos irinotecan give . Giving irinotecan together selenium may kill tumor cell . PURPOSE : This phase I trial study side effect best dose selenium give together irinotecan treat patient advance solid tumor .</brief_summary>
	<brief_title>Irinotecan Selenium Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine optimal load maintenance dos selenium necessary achieve selenium concentration exceed 15 μM administer irinotecan patient advance solid tumor . Secondary - Determine pharmacokinetics regimen patient . - Determine toxic effect regimen patient . - Determine observe tumor response regimen patient . OUTLINE : This dose-escalation study selenium . Patients receive load dose* oral selenium twice daily day -6 0 . Patients receive oral selenium daily day 1-42 irinotecan IV 90 minute day 1 , 8 , 15 , 22 . Courses repeat every 42 day absence disease progression unacceptable toxicity . NOTE : *The load dose administer prior course 1 . Cohorts 3-6 patient receive escalate dos selenium maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . PROJECTED ACCRUAL : A total 2-36 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor Metastatic unresectable disease Standard curative palliative treatment exist longer effective OR treatment singleagent irinotecan constitute reasonable treatment option No known untreated progressive brain metastasis Previously treat brain metastasis allow provided follow true : No significant neurological deficit No requirement antiepileptic medication Disease stable brain CT scan MRI PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy At least 12 week Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal AST ALT ≤ 3 time upper limit normal Albumin ≥ 3.0 g/dL No Gilbert 's disease Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No clinically significant cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able receive oral medication No active inflammatory bowel disease chronic diarrhea No known HIV positivity No history allergic reaction attribute compound similar chemical biologic composition study drug No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent prophylactic filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy At least 4 week since prior chemotherapy ( 6 week carmustine mitomycin ) Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy Surgery Not specify Other No concurrent investigational agent No concurrent anticancer therapy No concurrent Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>